Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3858279 in moderate to severe knee osteoarthritis pain
NCT05838742Phase 2Terminated
- Sponsor
- GSK
- Start
- Sep 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of GSK3858279 in osteoarthritis (OA) (5 arms), sponsored by GSK. Primary endpoint: Change From Baseline in Weekly Average of Average Daily Knee Pain Intensity Using Numeric Rating Scale at Week 12. Started Sep 2023; status: terminated.
02
Drugs
GSK3858279
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05838742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05838742.